大須賀崇裕

Osuga Takahiro

所属機関・部署：

研究分野 (1件)：腫瘍診断、治療学

競争的資金等の研究課題 (6件)：

2021 - 2024 CARとCIML NK細胞を用いた新規固形癌治療の開発
2020 - 2023 膵臓癌に対する抗がん剤の腫瘍指向性を持つ新規DDSの開発
2019 - 2022 低酸素誘導因子 (HIF)-1αの新規経路に着目した進行胃がん治療戦略の開発
2017 - 2020 細胞の糖代謝特性を利用した新規大腸癌治療法の開発
2015 - 2016 FUTを標的とした進行大腸癌に対する抗EMT療法の開発

全件表示

論文 (28件)：

Ryo Ito, Koji Miyanishi, Tomohiro Kubo, Kota Hamaguchi, Takahiro Osuga, Shingo Tanaka, Hiroyuki Ohnuma, Kazuyuki Murase, Kohichi Takada, Minoru Nagayama, et al. Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma. Hepatology international. 2023. 17. 3. 735-744
Kota Hamaguchi, Koji Miyanishi, Takahiro Osuga, Shingo Tanaka, Ryo Ito, Hiroki Sakamoto, Tomohiro Kubo, Hiroyuki Ohnuma, Kazuyuki Murase, Kohichi Takada, et al. Association between Hepatic Oxidative Stress Related Factors and Activation of Wnt/β-Catenin Signaling in NAFLD-Induced Hepatocellular Carcinoma. Cancers. 2022. 14. 9
Takahiro Osuga, Koji Miyanishi, Kota Hamaguchi, Shingo Tanaka, Hiroyuki Ohnuma, Kazuyuki Murase, Kohichi Takada, Junji Kato. A case of acute exacerbation of chronic hepatitis C during the course of adrenal Cushing's syndrome. Clinical Case Reports. 2022. 10. 2
Takahiro Osuga, Koji Miyanishi, Ryo Ito, Shingo Tanaka, Kota Hamaguchi, Hiroyuki Ohnuma, Kazuyuki Murase, Kohichi Takada, Minoru Nagayama, Yasutoshi Kimura, et al. A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib. Case reports in oncology. 2022. 15. 1. 318-325
Yusuke Sugama, Koji Miyanishi, Takahiro Osuga, Shingo Tanaka, Kota Hamaguchi, Ryo Ito, Hiroki Sakamoto, Tomohiro Kubo, Hiroyuki Ohnuma, Kazuyuki Murase, et al. Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy. JGH Open. 2021. 5. 12. 1335-1343

MISC (9件)：

Hiroyuki Ohnuma, Yasushi Sato, Naotaka Hayasaka, Teppei Matsuno, Chisa Fujita, Masanori Sato, Takahiro Osuga, Masahiro Hirakawa, Koji Miyanishi, Tamotsu Sagawa, et al. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study. Cancer science. 2018. 109. 11. 3554-3563
大沼啓之, 佐藤康史, 大須賀崇裕, 林毅, 佐藤勉, 宮西浩嗣, 小船雅義, 瀧本理修, 加藤淳二, 佐川保, et al. 進行食道癌に対するdocetaxel、nedaplatin、5-FU、放射線同時併用療法(DNF-R)の第I/II相試験. 北海道医学雑誌. 2015. 90. 2. 152-153
Y. Sato, H. Ohnuma, M. Hirakawa, T. Osuga, Y. Okagawa, T. Sagawa, Y. Takahashi, M. Takahashi, M. Maeda, S. Katsuki, et al. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a multi-institute retrospective study. EUROPEAN JOURNAL OF CANCER. 2015. 51. S431-S431
Junji Kato, Rishu Takimoto, Takahiro Osuga, Michihiro Ono, Yutaka Okagawa, Naoki Uemura, Yohei Arihara, Yasushi Sato, Fumito Tamura. Accumulation of L-Fucose Is a Functional Target for Colorectal Cancer Therapy. GASTROENTEROLOGY. 2015. 148. 4. S948-S948
Yasushi Sato, Hiroyuki Ohnuma, Masahiro Hirakawa, Yutaka Okagawa, Takahiro Osuga, Kazuyuki Murase, Kohichi Takada, Yutaka Kawano, Satoshi Iyama, Tsuyoshi Hayashi, et al. A phase I/II study of definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for advanced esophageal cancer. JOURNAL OF CLINICAL ONCOLOGY. 2015. 33. 3

学歴 (2件)：

2011 - 2015 札幌医科大学大学院医学研究科
2003 - 2009 札幌医科大学医学部医学科

経歴 (6件)：

2018/04 - 現在札幌医科大学腫瘍内科学講座助教
2016/04 - 2018/03 Massachusetts General Hospital GI Unit Postdoctoral Research Fellow
2015/04 - 2016/03 札幌医科大学腫瘍内科学講座
2011/04 - 2015/03 札幌医科大学大学院医学研究科大学院生
2009/04 - 2011/03 札幌医科大学附属病院臨床研修センター臨床研修医

全件表示

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

大須賀 崇裕

大須賀崇裕